Amgen’s Vectibix scores first-line approval in wild-KRAS colorectal cancer

John Carroll

The FDA has OK'd the use of Amgen's as a first-line treatment for wild-type KRAS metastatic . The agency approved the frontline use of the drug in combination with Folfox chemotherapy.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS